Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states.
Small-molecule correctors divert CFTR-F508del from ERAD by stabilizing sequential folding states.
复制标题
小分子校正剂通过稳定顺序折叠状态将 CFTR-F508del 从 ERAD 中转移。
DOI:
10.1091/mbc.e23-08-0336
复制
发表时间:
2024
影响因子:
3.3
通讯作者:
Kopito,RonR
中科院分区:
文献类型:
--
作者:
Riepe,Celeste;Wąchalska,Magda;Deol,KirandeepK;Amaya,AnaisK;Porteus,MatthewH;Olzmann,JamesA;Kopito,RonR
Over 80% of people with cystic fibrosis (CF) carry the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride ion channel at the apical plasma membrane (PM) of epithelial cells. F508del impairs CFTR folding causing it to be destroyed by endoplasmic reticulum associated degradation (ERAD). Small-molecule correctors, which act as pharmacological chaperones to divert CFTR-F508del from ERAD, are the primary strategy for treating CF, yet corrector development continues with only a rudimentary understanding of how ERAD targets CFTR-F508del. We conducted genome-wide CRISPR/Cas9 knockout screens to systematically identify the molecular machinery that underlies CFTR-F508del ERAD. Although the ER-resident ubiquitin ligase, RNF5 was the top E3 hit, knocking outRNF5only modestly reduced CFTR-F508del degradation. Sublibrary screens in anRNF5knockout background identified RNF185 as a redundant ligase and demonstrated that CFTR-F508del ERAD is robust. Gene-drug interaction experiments illustrated that correctors tezacaftor (VX-661) and elexacaftor (VX-445) stabilize sequential, RNF5-resistant folding states. We propose that binding of correctors to nascent CFTR-F508del alters its folding landscape by stabilizing folding states that are not substrates for RNF5-mediated ubiquitylation.